RU2010148803A - Способы применения кортикотропин-рилизинг фактора для лечения рака - Google Patents
Способы применения кортикотропин-рилизинг фактора для лечения рака Download PDFInfo
- Publication number
- RU2010148803A RU2010148803A RU2010148803/15A RU2010148803A RU2010148803A RU 2010148803 A RU2010148803 A RU 2010148803A RU 2010148803/15 A RU2010148803/15 A RU 2010148803/15A RU 2010148803 A RU2010148803 A RU 2010148803A RU 2010148803 A RU2010148803 A RU 2010148803A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- administered
- crf
- cancer
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 13
- 201000011510 cancer Diseases 0.000 title claims 3
- 238000011282 treatment Methods 0.000 title claims 3
- 239000003488 releasing hormone Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 62
- 208000003174 Brain Neoplasms Diseases 0.000 claims abstract 18
- 206010061309 Neoplasm progression Diseases 0.000 claims abstract 8
- 230000005751 tumor progression Effects 0.000 claims abstract 8
- 229920000249 biocompatible polymer Polymers 0.000 claims abstract 4
- 238000012544 monitoring process Methods 0.000 claims abstract 4
- 206010003571 Astrocytoma Diseases 0.000 claims abstract 3
- 206010014967 Ependymoma Diseases 0.000 claims abstract 3
- 208000032612 Glial tumor Diseases 0.000 claims abstract 3
- 206010018338 Glioma Diseases 0.000 claims abstract 3
- 208000000172 Medulloblastoma Diseases 0.000 claims abstract 3
- 206010027476 Metastases Diseases 0.000 claims abstract 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims abstract 3
- 210000004556 brain Anatomy 0.000 claims abstract 3
- 208000005017 glioblastoma Diseases 0.000 claims abstract 3
- 206010027191 meningioma Diseases 0.000 claims abstract 3
- 230000009401 metastasis Effects 0.000 claims abstract 3
- 238000011269 treatment regimen Methods 0.000 claims 20
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical group O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 6
- 229960004964 temozolomide Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 230000001394 metastastic effect Effects 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4929208P | 2008-04-30 | 2008-04-30 | |
| US61/049,292 | 2008-04-30 | ||
| US9480608P | 2008-09-05 | 2008-09-05 | |
| US61/094,806 | 2008-09-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010148803A true RU2010148803A (ru) | 2012-06-10 |
Family
ID=41119761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010148803/15A RU2010148803A (ru) | 2008-04-30 | 2009-04-30 | Способы применения кортикотропин-рилизинг фактора для лечения рака |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20100113341A1 (https=) |
| EP (1) | EP2259793A2 (https=) |
| JP (1) | JP2011519375A (https=) |
| KR (1) | KR20110021820A (https=) |
| CN (1) | CN102036680A (https=) |
| AU (1) | AU2009241813A1 (https=) |
| CA (1) | CA2722426A1 (https=) |
| CO (1) | CO6300959A2 (https=) |
| CR (1) | CR11762A (https=) |
| EC (1) | ECSP10010631A (https=) |
| IL (1) | IL209005A0 (https=) |
| MX (1) | MX2010011882A (https=) |
| NI (1) | NI201000185A (https=) |
| NZ (1) | NZ588877A (https=) |
| RU (1) | RU2010148803A (https=) |
| WO (1) | WO2009134396A2 (https=) |
| ZA (1) | ZA201007729B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010057962A2 (en) * | 2008-11-19 | 2010-05-27 | Neutron Limited | Crf conjugates with extended half-lives |
| CA2766322A1 (en) * | 2009-06-24 | 2010-12-29 | Stephen Evans-Freke | Methods of using corticotropin-releasing factor for the treatment of cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2852054A (en) * | 1956-11-23 | 1958-09-16 | Motley Murat Brunson | Container and closure therefor |
| US4312523A (en) * | 1979-10-29 | 1982-01-26 | Paco Packaging Incorporated | Label for container having pharmaceutical product therein |
| US4415558A (en) | 1981-06-08 | 1983-11-15 | The Salk Institute For Biological Studies | CRF And analogs |
| AU9054582A (en) | 1982-09-29 | 1984-04-24 | Lederis, K.P., Mac Cannell, K.L.:ichikawa, T:river, J.E. | Urotensin peptides |
| US4528189A (en) | 1983-02-03 | 1985-07-09 | The Salk Institute For Biological Studies | Urotensin peptides |
| US4489163A (en) * | 1983-04-14 | 1984-12-18 | The Salk Institute For Biological Studies | rCRF and analogs |
| US5391485A (en) * | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5342940A (en) * | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5229940A (en) * | 1992-01-29 | 1993-07-20 | Conoco Inc. | Method of extracting three dimensional information from a grid of two dimensional seismic data |
| US5360352A (en) * | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5780431A (en) * | 1996-09-20 | 1998-07-14 | Neurobiological Technologies, Inc. | Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form |
| US6319900B1 (en) * | 1999-09-21 | 2001-11-20 | The Regents Of The University Of California | Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
| CN1361180A (zh) * | 2000-12-26 | 2002-07-31 | 上海博德基因开发有限公司 | 一种新的多肽——促肾上腺皮质激素释放因子8.8和编码这种多肽的多核苷酸 |
| CN1382700A (zh) * | 2001-04-26 | 2002-12-04 | 上海博德基因开发有限公司 | 一种多肽——促肾上腺皮质激素释放因子－12.87和编码这种多肽的多核苷酸 |
| CA2358177A1 (en) * | 2001-10-03 | 2003-04-03 | Ted Ramsay | Label for pharmaceutical prescriptions |
| WO2004100997A2 (en) * | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Spacer moiety for poly(ethylene glycol) -modified peptides |
| MXPA06014021A (es) * | 2004-06-04 | 2007-02-08 | Pfizer Prod Inc | Procedimiento para tratar crecimiento celular anormal. |
| BRPI0513062A (pt) * | 2004-07-08 | 2008-04-22 | Aimsco Ltd | composição farmacêutica, método de estimular a produção de pomc em um paciente, usos de um peptìdeo de crf isolado e de um peptìdeo de pomc isolado, e, métodos de tratamento para uma doença, de produzir crf e de tratamento curativo, melhorador ou profilático de uma doença |
| JP2006036013A (ja) * | 2004-07-27 | 2006-02-09 | Yamaha Motor Co Ltd | 自動二輪車 |
| US7311205B2 (en) * | 2005-01-25 | 2007-12-25 | Target Brands, Inc. | Pharmacy bottle system including label |
| US20100203048A1 (en) * | 2008-04-30 | 2010-08-12 | Stephen Evans-Freke | Methods of using corticotropin-releasing factor for the use of the treatment of cancer |
-
2009
- 2009-04-30 RU RU2010148803/15A patent/RU2010148803A/ru not_active Application Discontinuation
- 2009-04-30 KR KR1020107026626A patent/KR20110021820A/ko not_active Withdrawn
- 2009-04-30 WO PCT/US2009/002645 patent/WO2009134396A2/en not_active Ceased
- 2009-04-30 US US12/433,652 patent/US20100113341A1/en not_active Abandoned
- 2009-04-30 JP JP2011507449A patent/JP2011519375A/ja active Pending
- 2009-04-30 EP EP09739199A patent/EP2259793A2/en not_active Withdrawn
- 2009-04-30 MX MX2010011882A patent/MX2010011882A/es not_active Application Discontinuation
- 2009-04-30 NZ NZ588877A patent/NZ588877A/xx not_active IP Right Cessation
- 2009-04-30 CN CN2009801188091A patent/CN102036680A/zh active Pending
- 2009-04-30 AU AU2009241813A patent/AU2009241813A1/en not_active Abandoned
- 2009-04-30 CA CA2722426A patent/CA2722426A1/en not_active Abandoned
-
2010
- 2010-10-27 CR CR11762A patent/CR11762A/es not_active Application Discontinuation
- 2010-10-28 IL IL209005A patent/IL209005A0/en unknown
- 2010-10-28 ZA ZA2010/07729A patent/ZA201007729B/en unknown
- 2010-10-28 NI NI201000185A patent/NI201000185A/es unknown
- 2010-11-23 CO CO10146559A patent/CO6300959A2/es not_active Application Discontinuation
- 2010-11-24 EC EC2010010631A patent/ECSP10010631A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NI201000185A (es) | 2013-04-22 |
| WO2009134396A2 (en) | 2009-11-05 |
| CO6300959A2 (es) | 2011-07-21 |
| JP2011519375A (ja) | 2011-07-07 |
| US20100113341A1 (en) | 2010-05-06 |
| EP2259793A2 (en) | 2010-12-15 |
| CN102036680A (zh) | 2011-04-27 |
| ZA201007729B (en) | 2014-02-26 |
| NZ588877A (en) | 2012-08-31 |
| CA2722426A1 (en) | 2009-11-05 |
| CR11762A (es) | 2011-04-26 |
| ECSP10010631A (es) | 2011-02-28 |
| AU2009241813A1 (en) | 2009-11-05 |
| KR20110021820A (ko) | 2011-03-04 |
| IL209005A0 (en) | 2011-01-31 |
| MX2010011882A (es) | 2011-02-25 |
| WO2009134396A3 (en) | 2010-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000357A (es) | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). | |
| CY1112473T1 (el) | Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα | |
| EA201270570A1 (ru) | Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90 | |
| UA92907C2 (uk) | Похідні тетрагідроіндазолону | |
| WO2011031474A3 (en) | Use of metformin in cancer treatment and prevention | |
| IN2012DN02826A (https=) | ||
| WO2007075554A3 (en) | Combination of igfr inhibitor and anti-cancer agent | |
| EA201201159A1 (ru) | Дейтерированные соединения пирролопиримидина в качестве ингибиторов cdk4/6 | |
| RU2008130963A (ru) | Лечение метастатического рака молочной железы | |
| MXPA02011913A (es) | Triazolopirimidinas sustituidas como agentes anticancer. | |
| WO2006130688A3 (en) | Compounds for inhibiting cathepsin activity | |
| WO2001074376A3 (en) | Cathepsin inhibitors in cancer treatment | |
| WO2012159085A3 (en) | Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells | |
| ATE308515T1 (de) | Antizymmodulatoren sowie deren verwendung | |
| RU2011108486A (ru) | ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ПЕПТИДА Wnt5-a ДЛЯ ЛЕЧЕНИЯ МЕЛАНОМЫ И РАКА ЖЕЛУДКА | |
| RU2005129273A (ru) | Противораковый агент, содержащий белок lk8 в качестве активного ингредиента | |
| RU2009146882A (ru) | Комбинированная противораковая терапия, включающая применение винфлунина и трастуцумаба | |
| RU2010148803A (ru) | Способы применения кортикотропин-рилизинг фактора для лечения рака | |
| EA200601249A1 (ru) | Пиперазины, пригодные для лечения боли | |
| RU2003118131A (ru) | Способ лечения ран | |
| RU2012102259A (ru) | Способы применения кортикотропин-рилизинг фактора для лечения рака | |
| NZ587941A (en) | Methods to inhibit tumor cell growth by using lansoprazole | |
| GB2426517A (en) | Methods and agents for inhibiting dynamin-dependent endocytosis | |
| MX2010004314A (es) | Compuestos para inhibir la actividad de quinesina de la proteina quinesina del huso. | |
| WO2019241641A3 (en) | Cancer treatment methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20131002 |